Follow
Victoria Yan
Title
Cited by
Cited by
Year
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
VC Yan, FL Muller
ACS Medicinal Chemistry Letters 11 (7), 1361–1366, 2020
1702020
NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis
MK Park, L Zhang, KW Min, JH Cho, CC Yeh, H Moon, ...
Cell metabolism 33 (12), 2380-2397. e9, 2021
1372021
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers
YH Lin, N Satani, N Hammoudi, VC Yan, Y Barekatain, S Khadka, ...
Nature Metabolism 2, 1413–1426, 2020
622020
Why Great Mitotic Inhibitors Make Poor Cancer Drugs
VC Yan, HE Butterfield, AH Poral, MJ Yan, KL Yang, CD Pham, FL Muller
Trends in Cancer 6 (11), 924-941, 2020
612020
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
VC Yan, FL Muller
Antimicrobial Agents and Chemotherapy 65 (10), e01117-21, 2021
372021
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
Y Barekatain, JJ Ackroyd, VC Yan, S Khadka, L Wang, KC Chen, ...
Nature communications 12 (1), 4228, 2021
332021
An optimized bioassay for screening combined anticoronaviral compounds for efficacy against feline infectious peritonitis virus with pharmacokinetic analyses of GS-441524 …
S Cook, L Wittenburg, VC Yan, JH Theil, D Castillo, KL Reagan, ...
Viruses 14 (11), 2429, 2022
252022
Caspase-3 substrates for noninvasive pharmacodynamic imaging of apoptosis by PET/CT
BJ Engel, ST Gammon, R Chaudhari, Z Lu, F Pisaneschi, H Yang, ...
Bioconjugate Chemistry 29 (9), 3180-3195, 2018
222018
Targeting host glycolysis as a strategy for antimalarial development
AJ Jezewski, YH Lin, JA Reisz, R Culp-Hill, Y Barekatain, VC Yan, ...
Frontiers in Cellular and Infection Microbiology 11, 730413, 2021
162021
Eradication of ENO1-deleted glioblastoma through collateral lethality
YH Lin, N Satani, N Hammoudi, JJ Ackroyd, S Khadka, VC Yan, ...
bioRxiv, 331538, 2018
162018
Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir’s Nephrotoxicity
VC Yan, FL Muller
Antimicrobial Agents and Chemotherapy 64 (12), e01920-20, 2020
152020
The 3S Enantiomer Drives Enolase Inhibitory Activity in SF2312 and Its Analogues
F Pisaneschi, YH Lin, PG Leonard, N Satani, VC Yan, N Hammoudi, ...
Molecules 24 (13), 2510, 2019
142019
Pharmacokinetics of Orally Administered GS-441524 in Dogs
VC Yan, S Khadka, K Arthur, CD Pham, MJ Yan, AJ Yan, JJ Ackroyd, ...
bioRxiv, 2021
122021
Antimicrobial prodrug activation by the staphylococcal glyoxalase GloB
MO Mikati, JJ Miller, DM Osbourn, Y Barekatain, N Ghebremichael, ...
ACS infectious diseases 6 (11), 3064-3075, 2020
112020
Remdesivir for COVID-19: Why Not Dose Higher?
VC Yan, FL Muller
Antimicrobial Agents and Chemotherapy 65, e2713-20, 2021
102021
Comprehensive summary supporting clinical investigation of GS-441524 for Covid-19 treatment
V Yan, F Muller
OSF Preprints, 2020
82020
Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers
VC Yan, CD Pham, ES Ballato, KL Yang, K Arthur, S Khadka, ...
Journal of Medicinal Chemistry 65 (20), 13813-13832, 2022
72022
Aliphatic amines are viable pro-drug moieties in phosphonoamidate drugs
VC Yan, CD Pham, K Arthur, KL Yang, FL Muller
Bioorganic & Medicinal Chemistry Letters 30 (24), 127656, 2020
72020
Enolase inhibitors as therapeutic leads for Naegleria fowleri infection
JE Milanes, VC Yan, CD Pham, F Muller, S Kwain, KC Rees, BN Dominy, ...
PLoS pathogens 20 (8), e1012412, 2024
62024
Gilead should ditch remdesivir and focus on its simpler and safer ancestor
VC Yan, FL Muller
Boston Globe Media Partners, 2020
62020
The system can't perform the operation now. Try again later.
Articles 1–20